Transarterial chemoembolization (TACE) is a standard treatment for intermediate-stage hepatocellular carcinoma (HCC), but response is highly variable. The systemic metabolic impact of TACE and its connection to tumor-intrinsic factors governing efficacy remain poorly understood. We hypothesized that by comparing host fecal metabolomics with tumor transcriptomics, we could identify convergent pathways suggestive of a gut-liver axis signature of TACE response.

Real-time endoscopic diagnosis of Helicobacter pylori infection remains challenging and often requires biopsy-based testing, delaying treatment decisions. Although deep learning (DL) approaches have shown promise, most prior studies have relied on retrospective datasets or image-enhanced modalities, limiting their applicability to routine white-light endoscopy. We aimed to develop and prospectively validate a research-stage DL model for H. pylori detection using only standard white-light endoscopic images.

Effector T lymphocytes have been found to play a key role in inflammatory bowel diseases (IBDs). However, the molecular pathways controlling their metabolism and functional activity remain poorly defined. We aimed to elucidate the role of the immune checkpoint receptor TIM3 for T-cell signaling in IBDs.

Early-onset gastric cancer (EOGC), diagnosed before age 45, demonstrates distinct clinicopathological features and poorer prognosis. Current screening strategies lack sensitivity in young populations, while Helicobacter pylori (H. pylori) virulence genotypes (e.g., cagA, vacA) remain underutilized in risk stratification. To develop and validate a diagnostic model combining clinical characteristics and H. pylori virulence serological detection of virulence factors to optimize EOGC risk stratification.

Inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, are chronic conditions associated with gastrointestinal inflammation and a wide range of extraintestinal manifestations. While conventional treatments primarily address intestinal inflammation, many patients continue to experience chronic pain, psychological comorbidities, and functional gastrointestinal symptoms, highlighting the need for integrated therapeutic strategies. This narrative review explores the potential of neurofeedback (NFB) as a non-invasive therapeutic approach for managing symptoms frequently observed in IBD, including musculoskeletal pain, anxiety, depression, post-traumatic stress symptoms (PTSS), and gut-brain axis dysfunction. In the absence of direct evidence on neurofeedback in IBD populations, we examined data from clinical trials conducted in conditions that are frequently comorbid with or symptomatically overlap with inflammatory bowel disease, including fibromyalgia, irritable bowel syndrome (IBS), chronic pain syndromes, and affective or trauma-related disorders. We focused on outcomes related to chronic pain, psychological well-being, and gastrointestinal function, examining NFB protocols primarily targeting alpha, theta, and sensorimotor rhythms, which have shown promising results in improving symptom severity and autonomic regulation. These findings support the rationale for investigating NFB as a potential adjunctive therapy in IBD, particularly for patients with residual or refractory extraintestinal symptoms. However, as none of the available studies specifically involve patients with IBD, the evidence base remains indirect. Moreover, current findings are limited by small sample sizes, heterogeneous methodologies, and variable outcome measures in the studied populations, making it difficult to draw definitive conclusions regarding the efficacy of NFB in this context. Future research should include large-scale, randomized controlled trials conducted directly in IBD cohorts, along with protocol standardization and individualized approaches based on neurophysiological profiles. Clarifying the therapeutic potential of NFB in this population could open new avenues for non-pharmacological, patient-tailored interventions within integrative care frameworks.

Acute pancreatitis (AP) demonstrates substantial heterogeneity across adult age groups; however, the relative contributions of chronological age, baseline vulnerability, acute organ dysfunction, and local disease complexity to short-term outcomes remain incompletely understood.

Gastroesophageal reflux disease (GERD) and major depressive disorder (MDD) frequently co-occur, yet their shared molecular mechanisms remain poorly understood. This study aimed to identify a robust gene signature linking GERD and MDD and to evaluate its clinical relevance.

Diabetic gastroparesis (DG) is a frequently underdiagnosed complication of type 2 diabetes mellitus (T2D), characterized by delayed gastric emptying without mechanical obstruction. Its nonspecific symptoms often lead to delayed diagnosis and suboptimal management.

Endoscopic submucosal dissection (ESD) is a well-accepted endoscopic resection modality for early-stage gastrointestinal tumors. Over the past decades, progressive refinements in instruments, traction methods, and closure techniques have enhanced the safety and efficacy of ESD, and ESD further evolves into conventional ESD (C-ESD), traction-assisted ESD (T-ESD), and underwater ESD (U-ESD). The three modalities have their distinct benefits and are complementary to each other in clinical practice. At the same time, they compete with one another, presenting a challenge to operators with respect to which to select in specific scenarios.

Whether collecting one or two fecal samples for immunochemical testing (FIT) optimizes colorectal cancer screening outcomes remains unclear.

There is a paucity of outcome data among homeless individuals with inflammatory bowel diseases (IBD). We reported rates of homelessness among inpatients with Crohn's disease (CD) and ulcerative colitis (UC) and examined inpatient outcomes.

The use of mobile health applications (apps) has a significant impact on lifestyle changes, especially in chronic diseases such as fatty liver disease, and provides a good opportunity for self-care and lifestyle improvement. This study aimed to systematically evaluate the quality of self-care mobile applications for fatty liver patients based on the MARS rating features.

Current guideline-defined indicators for fibrosis screening identify a large proportion of the general population, burdening health care resources. We aimed to evaluate and refine indicators for fibrosis screening.

Patients with chronic kidney disease (CKD) present a disordered short-chain fatty acid (SCFA)-intestinal barrier-protein-bound uremic toxin (PBUT) axis, while clinical guidelines lack strategies for PBUT source reduction. This study explored the regulatory effects of SCFAs to support individualized interventions for CKD patients.